Journals / Turkish Journal of Gastroenterology / 2004 / Cilt: 15 - Sayı: 4

Pantoprazol veya lansoprazol ile amoksisilin ve klaritromisin içeren rejimlerin Helikobakter pilori eradikasyonundaki güncel durumu

Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori

Pages
219–224
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The choice of proton pump inhibitor is not important in the eradication rate of H. pylori.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: There are some reports showing that resistance of Helicobacter pylori (H. pylori) to clarithromycin has increased in recent years.
📊
Key Findings & Data:Methods: Ninety patients with H. pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b.i.d. or lansoprazole 30 mg b.i.d. in addition to amoxicillin 1000 mg and clarithromycin 500 mg twice daily for 14 days in a multicenter study.
💡
Conclusion & Impact:The choice of proton pump inhibitor is not important in the eradication rate of H. pylori.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Amoksisilin · Klaritromisin · Helicobacter pylori

Abstract

Background/aims: There are some reports showing that resistance of Helicobacter pylori (H. pylori) to clarithromycin has increased in recent years. We aimed to investigate the current success of a most popular first-line eradication regimen by using two different proton pump inhibitors: lansoprazole and pantoprazole. Methods: Ninety patients with H. pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b.i.d. or lansoprazole 30 mg b.i.d. in addition to amoxicillin 1000 mg and clarithromycin 500 mg twice daily for 14 days in a multicenter study. H. pylori infection was determined by histological examination and a rapid urease test. A follow-up endoscopy was performed to assess the H. pylori eradication six weeks after the end of therapy. Results: Seventy-nine patients completed the study protocol properly. The H. pylori eradication rates according to per protocol analysis were 70% in group pantoprazole, amoxicillin and clarithromycin (28/40) and 69.2% in group pantoprazole, amoxicillin and clarithromycin (27/39). The eradication rates according to intention to treat analysis were 62.2% and 60% in lansoprazole, amoxicillin, clarithromycin, pantoprazole, amoxicillin, clarithromycin groups, respectively. The eradication rates were similar in both protocols (p>0.05). Conclusions: The most popular first-line eradication protocols of H. pylori achieved only a moderate success in the current study. Alternative therapy options are needed instead of clarithromycin-based triple treatment for eradication of H. pylori. The choice of proton pump inhibitor is not important in the eradication rate of H. pylori.

Özet

Amaç: Son yıllarda H. pylorinin klaritromisine karşı direncinin arttığına dair çok sayıda çalışma bildirilmektedir. Bu çalışmada H.pylori eradikasyonunda en çok kullanılan ilk basamak eradikasyon şemasının güncel başarısının iki farklı proton pompa inhibitörü; pantoprazol ve lansoprazol kullanılarak araştırılması amaçlandı. Yöntem: H. pylori pozitif fonksiyonel dispepsisi olan 90 hasta çok merkezli bir çalışmada pantoprazol 2x40mg veya lansoprazol 2x30mg ile birlikte amoksisilin 2x1000mg ve klaritromisin 2x500mg 14 gün süreyle alacak şekilde 2 ayrı gruba randomize edildi. H. pylori histoloji ve hızlı üreaz testi ile belirlendi. Eradikasyon tedavisinden 6 hafta sonra kontrol endokopi yapılarak H. pylori araştırıldı. Bulgular: Yetmişdokuz hasta protokolü tamamladı. Per protokol analizinde pantoprazol, amoksisilin, klaritromisin grubunda %70 (28/40), lansoprazol, amoksisilin, klaritromisin grubunda %69.2 (27/39) eradikasyon saptandı. Tedavi hedeflenen gruptaki eradikasyon oranları pantoprazol, amoksisilin, klaritromisin grubunda %62.2, lansoprazol, amoksisilin, klaritromisin grubunda %60 olarak belirlendi. İki grup arasında eradikasyon oranları açısından fark saptanmadı (p>0.05) Sonuç: H. pylori için halen en popüler olan ve PPI, klaritromisin, amoksisilinden oluşan ilk basamak eradikasyon rejimi bu çalışmada orta derecede bir başarı sağlamıştır. H. pylori eradikasyonunda alternatif tedavilere ihtiyaç vardır. Proton pompa inhibitör seçimi eradikasyonun başarısını etkilememektedir.

🔖

Cite This Article

UYGUN, A., KADAYIFÇI, A., YEŞİLOVA, Z., SAVAŞ, M. C., ATEŞ, Y., KARSLIOĞLU, Y., CİĞERİM, M., BAĞCI, S., DAĞALP, K. (2004). Pantoprazol veya lansoprazol ile amoksisilin ve klaritromisin içeren rejimlerin Helikobakter pilori eradikasyonundaki güncel durumu. Turkish Journal of Gastroenterology, Cilt: 15 - Sayı: 4, 219–224. https://ajindex.com/articles/411367

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobaeter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002
  2. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobaeter pylori infections. Ann Intern Med 2003
  3. Dupas JL. First line therapy for Helicobaeter pylori eradication in France. Gastroenterol Clin Biol 2003
  4. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003
  5. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobaeter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998
  6. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobaeter pylori in eastern Europe. Clin Microbiol Infect 2002
  7. Eun CS, Han DS, Park JY, et al. Changing pattern of antimicrobial resistance of Helicobaeter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 2003
  8. Önder GF, Aydin A, Akarca US, et al. Ülkemizde Helicobacter pylorinin klaritromisine direncinin real time PCR yöntemi ile araştırılması. Turk J Gastroenterol 2004: 15 (Suppl 1): 40. 9.Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996
  9. Lee JM, Breslin NP, Hyde DK, et al. Treatment options for Helicobaeter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999
  10. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. Helicobaeter 2003
  11. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobaeter pylori infection. Aliment Pharmacol Ther 2000
  12. Kadayifci A, Buyukhatipoglu H, Simsek I, et al. Türkiye'de H. pylori eradikasyonunda PPI kl